Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal Vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group I: Investigational MenABCWY Formulation 1 | EXPERIMENTAL | - |
| Group II: Investigational MenABCWY Formulation 2 | EXPERIMENTAL | - |
| Group III: Investigational MenABCWY Formulation 3 | EXPERIMENTAL | - |
| Group IV: Investigational MenABCWY Formulation 4 | EXPERIMENTAL | - |
| Group V: Active comparator investigational MenB | ACTIVE_COMPARATOR | - |
| Group VI: Active comparator MenACWY | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Meningococcal Vaccine | BIOLOGICAL | MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months. |
Inclusion Criteria: Individuals eligible to be enrolled into this study are male and female subjects: 1. 11-18 years at the time of enrollment; 2. who have given their written consent/assent and whose parents or legal guardians have given written informed consent at the time of enrollment; 3. who ...
Meningococcal Vaccine is used for the prevention of meningococcal disease, including meningococcal meningitis. It is an investigational vaccine being developed by Novartis AG for use in adolescents. The vaccine is designed to protect against infection caused by Neisseria meningitidis bacteria.
Meningococcal Vaccine is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is publicly traded on the New York Stock Exchange under the ticker symbol NVS. The vaccine is currently in clinical development for the prevention of meningococcal disease.
Meningococcal Vaccine is currently in Phase 2 clinical development. It is an investigational vaccine, meaning it has not yet been approved by regulatory authorities. The vaccine is being studied for its immunogenicity and safety in adolescents for the prevention of meningococcal disease.
Meningococcal Vaccine has been studied in one completed Phase 2 clinical trial, identified as NCT01210885. This trial, titled 'Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents,' enrolled 495 participants aged 11 years and older in Chile, Colombia, and Panama. The trial was active-controlled and included healthy volunteers.
Meningococcal Vaccine is a monoclonal antibody-based vaccine. It works by stimulating the immune system to produce antibodies against Neisseria meningitidis, the bacteria that cause meningococcal disease. The vaccine contains components designed to elicit a protective immune response against multiple serogroups of the bacteria.
Meningococcal Vaccine is being studied in combination with MenACWY, as indicated by the clinical trial title 'Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents.' The trial evaluated different formulations of the vaccine, suggesting that the meningococcal vaccine may be combined with other components to provide broader protection.